IGC Pharma, Inc. (IGC)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 03-31. Amounts in USD.

Revenue Quarterly

0 200K 400K 600K Q2 '22: 56K Q3 '22: 142K Q4 '22: 122K Q1 '23: 212K Q2 '23: 202K Q3 '23: 332K Q4 '23: 166K Q1 '24: 555K Q2 '24: 291K Q3 '24: 204K Q4 '24: 295K Q1 '25: 272K Q2 '25: 412K Q3 '25: 257K Q4 '25: 330K Q1 '26: 328K Q2 '26: 191K Q3 '26: 350K Q4 '26: 317K Q1 '27: 265K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Gross Profit Quarterly

0 90K 180K 270K Q2 '22: 38K Q3 '22: 62K Q4 '22: 68K Q1 '23: 142K Q2 '23: 135K Q3 '23: 102K Q4 '23: 63K Q1 '24: 255K Q2 '24: 174K Q3 '24: 133K Q4 '24: 171K Q1 '25: 163K Q2 '25: 198K Q3 '25: 104K Q4 '25: 154K Q1 '26: 154K Q2 '26: 99K Q3 '26: 44K Q4 '26: 55K Q1 '27: 48K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q2 '22: -4.3M Q3 '22: -2.4M Q4 '22: -6.5M Q1 '23: -2.8M Q2 '23: -2.5M Q3 '23: -2.3M Q4 '23: -4M Q1 '24: -2.1M Q2 '24: -2.5M Q3 '24: -3M Q4 '24: -2.2M Q1 '25: -2.4M Q2 '25: -1.8M Q3 '25: -1.9M Q4 '25: -1.4M Q1 '26: -1.9M Q2 '26: -2.9M Q3 '26: -2.9M Q4 '26: -2.5M Q1 '27: -2.8M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Net Income Quarterly

-7.5M -5M -2.5M 0 2.5M 5M 7.5M Q2 '22: -4.3M Q3 '22: -2.4M Q4 '22: -6.5M Q1 '23: -2.8M Q2 '23: -2.4M Q3 '23: -2.2M Q4 '23: -4M Q1 '24: -2.1M Q2 '24: -2.5M Q3 '24: -5.6M Q4 '24: -2.9M Q1 '25: -2.4M Q2 '25: -1.7M Q3 '25: -1.8M Q4 '25: -1.2M Q1 '26: -1.6M Q2 '26: -1.8M Q3 '26: -726K Q4 '26: -2.4M Q1 '27: -2.9M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Cost of Revenue Quarterly

0 150K 300K 450K Q2 '22: 18K Q3 '22: 80K Q4 '22: 54K Q1 '23: 70K Q2 '23: 67K Q3 '23: 230K Q4 '23: 103K Q1 '24: 300K Q2 '24: 117K Q3 '24: 71K Q4 '24: 124K Q1 '25: 109K Q2 '25: 214K Q3 '25: 153K Q4 '25: 176K Q1 '26: 174K Q2 '26: 92K Q3 '26: 306K Q4 '26: 262K Q1 '27: 217K Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating Cash Flow Quarterly

-2.7M -1.8M -900K 0 900K 1.8M 2.7M Q2 '22: -2.3M Q3 '22: -2.4M Q4 '22: -887K Q1 '23: -2.2M Q2 '23: -1.7M Q3 '23: -1.6M Q4 '23: -1.5M Q1 '24: -1.5M Q2 '24: -1.6M Q3 '24: -1.6M Q4 '24: -526K Q1 '25: -1.8M Q2 '25: -996K Q3 '25: -1.3M Q4 '25: -730K Q1 '26: -1.4M Q2 '26: -2.1M Q3 '26: -1.2M Q4 '26: -1.2M Q1 '27: -1.4M Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Free Cash Flow Quarterly

-2.7M -1.8M -900K 0 900K 1.8M 2.7M Q3 '21: -2M Q4 '21: -2.6M Q1 '22: -1.9M Q2 '22: -2.3M Q3 '22: -2.4M Q4 '22: -971K Q1 '23: -2.3M Q1 '24: -1.5M Q2 '24: -1.7M Q3 '24: -1.7M Q4 '24: -541K Q1 '25: -1.8M Q2 '25: -1M Q3 '25: -1.3M Q4 '25: -748K Q1 '26: -1.4M Q2 '26: -2.1M Q3 '26: -1.2M Q4 '26: -1.2M Q1 '27: -1.4M Q4 '21 Q3 '22 Q1 '24 Q4 '24 Q3 '25 Q2 '26 Q1 '27

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q1 '19: 31M Q3 '19: 39.5M Q1 '20: 39.5M Q3 '20: 39.6M Q1 '21: 40.2M Q1 '22: 47.9M Q1 '23: 51.6M Q2 '23: 52.2M Q3 '23: 53.1M Q1 '24: 53.1M Q2 '24: 54.3M Q3 '24: 63.7M Q1 '25: 72.8M Q2 '25: 76M Q3 '25: 77.6M Q4 '25: 79.7M Q1 '26: 83M Q2 '26: 90.5M Q4 '26: 98.2M Q1 '27: 100.3M Q3 '19 Q1 '21 Q2 '23 Q2 '24 Q2 '25 Q1 '26 Q1 '27

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q2 '20: -0.15 Q3 '20: -0.16 Q4 '20: -0.18 Q1 '21: -0.20 Q2 '21: -0.21 Q3 '21: -0.23 Q4 '21: -0.22 Q1 '22: -0.21 Q2 '22: -0.26 Q3 '22: -0.25 Q4 '24: -0.22 Q1 '25: -0.21 Q2 '25: -0.18 Q3 '25: -0.11 Q4 '25: -0.09 Q1 '26: -0.08 Q2 '26: -0.08 Q3 '26: -0.07 Q4 '26: -0.07 Q1 '27: -0.08 Q3 '20 Q2 '21 Q1 '22 Q4 '24 Q3 '25 Q2 '26 Q1 '27

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.